LINC1852 interacts with SRSF5, enhancing its degradation, which increases PKM1/PKM2 ratio and represses aerobic glycolysis, tumor growth and chemoresistance (Fig. 3H) [61]. The gene discussed is PKM; the disease is neoplasm.